Lindsay Mark F. has made a notable move by acquiring 12,000 stock options from Vivos Therapeutics, Inc. This transaction, reported in a recent SEC filing, is significant as it may enhance his influence within the company and the broader surgical and medical instruments industry.
The stock options were granted on September 14, 2026, and are part of a structured vesting schedule. According to the filing, one-half of the options vested immediately, with one-fourth set to vest on September 30, 2026, and the remaining one-fourth on December 31, 2026. This structured approach indicates a long-term commitment to Vivos Therapeutics, which focuses on innovative medical solutions.
Background
Vivos Therapeutics, Inc. is a company incorporated in Delaware and is primarily engaged in the surgical and medical instruments and apparatus sector. The company operates under the Central Index Key (CIK) number 0001716166 and has a fiscal year ending on December 31. The company previously operated under the name Vivos BioTechnologies, Inc., a name change that took effect on September 1, 2017.
What the Filing Says
In the recent filing dated October 26, 2026, Lindsay Mark F. reported the acquisition of 12,000 stock options, which he received as part of a grant from Vivos Therapeutics. The options are exercisable at a price of $0.18 per share, reflecting a strategic move to align his interests with the company's performance. The filing notes, "On September 14, 2026, the Reporting Person received a grant of 12,000 stock options from the Issuer." Following this transaction, Mark F. holds a total of 17,200 shares.
Impact
This acquisition may have several implications. For Vivos Therapeutics, it could signify a strengthening of leadership and a commitment to the company's future. Additionally, it may influence other stakeholders and investors who are closely monitoring the company's direction. The surgical and medical instruments industry, as a whole, may interpret this move as a sign of confidence in Vivos Therapeutics' growth potential.
What's Next
The filing does not say what happens next regarding further transactions or developments related to Mark F. Lindsay's stake in Vivos Therapeutics. However, the structured vesting schedule of the stock options suggests that there will be ongoing engagement and potential future transactions as the options vest.